FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294068994> ?p ?o ?g. }

• W4294068994 abstract "Abstract Background Gabapentin and pregabalin are commonly prescribed medications to treat pain in patients with diabetic neuropathy. Gabapentin and pregabalin can cause fluid retention, which is hypothesized to be associated with cardiovascular diseases. However, whether long-term use of gabapentin and pregabalin is associated with adverse cardiovascular diseases remains unknown. This study aims to examine the association between gabapentin use, pregabalin use and several adverse cardiovascular events. Methods This retrospective cohort study used propensity score matching within patient electronic health records (EHRs) from a multicenter database with 106 million patients from 69 health care organizations in the US. The study population comprised 210,064 patients who had a diagnosis of diabetic neuropathy and were prescribed diabetic neuropathy medications in their EHRs. The exposure cohort comprised patients who were prescribed gabapentin or pregabalin to treat diabetic neuropathy. The comparison cohort comprised patients who were not prescribed either gabapentin or pregabalin but were prescribed other drugs to treat diabetic neuropathy. The outcomes of interest were myocardial infarcts, strokes, heart failure, peripheral vascular disease, and venous thromboembolic events. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for 3-month and 5-year risk for adverse cardiovascular events between the propensity score-matched cohorts. Results Both gabapentin and pregabalin were associated with increased risk of 5-year adverse cardiovascular events compared with the comparison group. In patients prescribed gabapentin, the highest risk was observed for deep venous thrombosis (HR: 1.58, 95% CI 1.37–1.82), followed by pulmonary embolism (HR: 1.5, 95% CI 1.27–1.76), peripheral vascular disease (HR: 1.37, 95% CI 1.27–1.47), stroke (HR: 1.31, 95% CI 1.2–1.43), myocardial infarction (HR: 1.25, 95% CI 1.14–1.38) and heart failure (HR: 1.14, 95% CI 1.07–1.21). In patients prescribed pregabalin, the highest risk was observed for deep venous thrombosis (HR: 1.57, 95% CI 1.31–1.88), followed by peripheral vascular disease (HR: 1.35, 95% CI 1.22–1.49), myocardial infarction (HR: 1.29, 95% CI 1.13–1.47), pulmonary embolism (HR: 1.28, 95% CI 1.04–1.59), stroke (HR: 1.26, 95% CI 1.12–1.42), and heart failure (HR: 1.2, 95% CI 1.11–1.3). There were significant associations between short-term (3 month) gabapentin use and heart failure, myocardial infarction, peripheral vascular disease, deep venous thrombosis, and pulmonary embolism. Short-term (3 month) pregabalin use was associated with deep venous thrombosis, peripheral vascular disease. Conclusion In patients with diabetic neuropathy who were prescribed gabapentin and pregabalin, there is an increased risk for heart failure, myocardial infarction, peripheral vascular disease, stroke, deep venous thrombosis, and pulmonary embolism with long-term use. Our findings suggest that increased risk for adverse cardiovascular events, along with other side effects, the efficacy of pain control and the degree of tolerance of the patient, should be considered when prescribing gabapentin and pregabalin long-term in patients with diabetic neuropathy." @default.
• W4294068994 created "2022-09-01" @default.
• W4294068994 creator A5017992444 @default.
• W4294068994 creator A5019216444 @default.
• W4294068994 creator A5020838037 @default.
• W4294068994 creator A5021719854 @default.
• W4294068994 creator A5050134236 @default.
• W4294068994 date "2022-09-01" @default.
• W4294068994 modified "2023-10-14" @default.
• W4294068994 title "Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy" @default.
• W4294068994 cites W128331768 @default.
• W4294068994 cites W1586699954 @default.
• W4294068994 cites W1593442063 @default.
• W4294068994 cites W1931794981 @default.
• W4294068994 cites W1948854550 @default.
• W4294068994 cites W1954180228 @default.
• W4294068994 cites W1993911451 @default.
• W4294068994 cites W1997175144 @default.
• W4294068994 cites W2011276893 @default.
• W4294068994 cites W2018227915 @default.
• W4294068994 cites W2020353068 @default.
• W4294068994 cites W202508222 @default.
• W4294068994 cites W2027478301 @default.
• W4294068994 cites W2069733524 @default.
• W4294068994 cites W2080195990 @default.
• W4294068994 cites W2088576422 @default.
• W4294068994 cites W2100631748 @default.
• W4294068994 cites W2100771222 @default.
• W4294068994 cites W2115503933 @default.
• W4294068994 cites W2127637322 @default.
• W4294068994 cites W2135393211 @default.
• W4294068994 cites W2139776244 @default.
• W4294068994 cites W2147283693 @default.
• W4294068994 cites W2150180487 @default.
• W4294068994 cites W2155877918 @default.
• W4294068994 cites W2160662478 @default.
• W4294068994 cites W2161839753 @default.
• W4294068994 cites W2162435639 @default.
• W4294068994 cites W2265628036 @default.
• W4294068994 cites W2330496155 @default.
• W4294068994 cites W2419247392 @default.
• W4294068994 cites W2534376183 @default.
• W4294068994 cites W2581794827 @default.
• W4294068994 cites W2625113972 @default.
• W4294068994 cites W2737759567 @default.
• W4294068994 cites W2795233845 @default.
• W4294068994 cites W2808737328 @default.
• W4294068994 cites W2906398614 @default.
• W4294068994 cites W2924513576 @default.
• W4294068994 cites W2944136715 @default.
• W4294068994 cites W2999628417 @default.
• W4294068994 cites W3040720590 @default.
• W4294068994 cites W3105135969 @default.
• W4294068994 cites W3174757634 @default.
• W4294068994 cites W4200532428 @default.
• W4294068994 cites W4200607853 @default.
• W4294068994 cites W4221051456 @default.
• W4294068994 cites W4238538758 @default.
• W4294068994 doi "https://doi.org/10.1186/s12933-022-01610-9" @default.
• W4294068994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36050764" @default.
• W4294068994 hasPublicationYear "2022" @default.
• W4294068994 type Work @default.
• W4294068994 citedByCount "12" @default.
• W4294068994 countsByYear W42940689942022 @default.
• W4294068994 countsByYear W42940689942023 @default.
• W4294068994 crossrefType "journal-article" @default.
• W4294068994 hasAuthorship W4294068994A5017992444 @default.
• W4294068994 hasAuthorship W4294068994A5019216444 @default.
• W4294068994 hasAuthorship W4294068994A5020838037 @default.
• W4294068994 hasAuthorship W4294068994A5021719854 @default.
• W4294068994 hasAuthorship W4294068994A5050134236 @default.
• W4294068994 hasBestOaLocation W42940689941 @default.
• W4294068994 hasConcept C126322002 @default.
• W4294068994 hasConcept C134018914 @default.
• W4294068994 hasConcept C142724271 @default.
• W4294068994 hasConcept C167135981 @default.
• W4294068994 hasConcept C17923572 @default.
• W4294068994 hasConcept C197934379 @default.
• W4294068994 hasConcept C201903717 @default.
• W4294068994 hasConcept C204787440 @default.
• W4294068994 hasConcept C2776468701 @default.
• W4294068994 hasConcept C2776608144 @default.
• W4294068994 hasConcept C2777107010 @default.
• W4294068994 hasConcept C2779901536 @default.
• W4294068994 hasConcept C2908647359 @default.
• W4294068994 hasConcept C42219234 @default.
• W4294068994 hasConcept C555293320 @default.
• W4294068994 hasConcept C71924100 @default.
• W4294068994 hasConcept C72563966 @default.
• W4294068994 hasConcept C99454951 @default.
• W4294068994 hasConceptScore W4294068994C126322002 @default.
• W4294068994 hasConceptScore W4294068994C134018914 @default.
• W4294068994 hasConceptScore W4294068994C142724271 @default.
• W4294068994 hasConceptScore W4294068994C167135981 @default.
• W4294068994 hasConceptScore W4294068994C17923572 @default.
• W4294068994 hasConceptScore W4294068994C197934379 @default.
• W4294068994 hasConceptScore W4294068994C201903717 @default.
• W4294068994 hasConceptScore W4294068994C204787440 @default.
• W4294068994 hasConceptScore W4294068994C2776468701 @default.
• W4294068994 hasConceptScore W4294068994C2776608144 @default.

• next